A Study of Stapokibart Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Conditions: CRSWNP

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Enrollment: 600

Sponsor: Chengdu Kangnuoxing Biopharma,Inc.

Location: Beijing Tongren Hospital, CMU Beijing Beijing Municipality

Summary

This study is a open label, prospective study to evaluate the safety of Stapokibart Injection in subjects with CRSwNP.

Eligibility Criteria

Inclusion Criteria: * Participants aged 18 years or older at the time of informed consent and provide voluntary informed consent to participate in the study before inclusion in the study. * Physician decision to treat the participant with Stapokibart Injection for CRSwNP (according to the China-specific prescribing information) made prior to and independently of the participant's participation in the study. Exclusion Criteria: * Known history of allergic reaction to Stapokibart Injection. * Participants currently or plan participating in any interventional clinical trial. * Participants with hematologic malignancies. * Women with pregnant. * Any condition that, in the opinion of the Investigator, may interfere with the participant's ability to participate in the study.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07483268). StuddyBuddy aggregates publicly available trial information.